Overview

Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer

Status:
Completed
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to evaluate the efficacy of TAS-118 plus Oxaliplatin compared with S-1 plus Cisplatin in overall survival in patients with advanced gastric cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Taiho Pharmaceutical Co., Ltd.
Collaborator:
Yakult Honsha Co., LTD
Treatments:
Cisplatin
Oxaliplatin